Westlake Village BioPartners

Westlake Village BioPartners is a venture capital firm established in 2018 and based in Los Angeles, California. The firm specializes in incubating and developing early-stage life sciences companies, with a particular emphasis on biotech and pharmaceutical sectors. It partners with entrepreneurs to cultivate transformative therapies and technologies aimed at improving patient outcomes. The firm's approach leverages the founding team's extensive experience in identifying, developing, and commercializing breakthrough medical innovations. By providing initial seed funding, Westlake Village BioPartners supports the early stages of technology development before engaging in more substantial financing rounds.

Mira Chaurushiya

Managing Director

Eric Kaufman

Senior Associate

Brogan Perrelli

Vice President Finance and Operations

28 past transactions

Latigo Biotherapeutics

Series B in 2025
Latigo Biotherapeutics is a clinical-stage biotechnology company that develops novel, non-opioid therapies for chronic pain. The company aims to target pain at its source to provide effective, rapid-acting pain relief without the risk of addiction. Their lead program targets Nav1.8, a validated human pain target, leveraging internal ion channel expertise.

Borealis Biosciences

Series A in 2024
Borealis Biosciences is a discovery-stage biotechnology company focused on developing next-generation RNA-based therapies, particularly targeting kidney diseases. The company specializes in molecular and cellular biology, chemistry, and analytical capabilities, utilizing these strengths to identify and map target opportunities within specific patient subsets affected by kidney conditions. Borealis aims to enhance the delivery mechanisms of RNA medicines to distinct cell types, thereby addressing significant unmet medical needs in the treatment of kidney diseases.

ArsenalBio

Series C in 2024
ArsenalBio is a programmable cell therapy company established in 2019, focused on developing and commercializing innovative immune cell therapies, particularly for cancer treatment. The company utilizes advanced technologies, including CRISPR-based genome engineering, synthetic biology, and machine learning, to create multifunctional T-cell therapies. ArsenalBio's approach involves the precise insertion of large synthetic DNA sequences, enabling the generation of next-generation autologous T-cell therapies. By integrating these cutting-edge methods, ArsenalBio aims to enhance the effectiveness and safety of immune cell therapies, reduce costs for healthcare providers, and improve market access, ultimately broadening patient outcomes and making these therapies more widely available.

Latigo Biotherapeutics

Series A in 2024
Latigo Biotherapeutics is a clinical-stage biotechnology company that develops novel, non-opioid therapies for chronic pain. The company aims to target pain at its source to provide effective, rapid-acting pain relief without the risk of addiction. Their lead program targets Nav1.8, a validated human pain target, leveraging internal ion channel expertise.

Star Therapeutics

Series C in 2023
Star Therapeutics is a biotechnology company focused on developing innovative therapies for a wide range of rare diseases. The company aims to identify rare diseases that share common biological mechanisms, allowing it to create novel therapeutics capable of treating multiple conditions with a single treatment. This approach not only enhances the potential for effective solutions but also provides pharmaceutical companies with opportunities to address several rare diseases simultaneously. By targeting a diverse array of conditions, Star Therapeutics strives to significantly improve the lives of millions of patients affected by these challenging health issues.

Kyverna Therapeutics

Series B in 2023
Kyverna Therapeutics, Inc. is a cell therapy company focused on developing innovative treatments and potential cures for serious autoimmune diseases. Founded in 2018 and based in Berkeley, California, the company utilizes advanced T cell engineering and synthetic biology technologies to target and eliminate autoreactive immune cells that contribute to inflammatory conditions. By addressing the underlying causes of these diseases, Kyverna Therapeutics aims to offer effective solutions for patients suffering from autoimmune disorders.

Kate Therapeutics

Series A in 2023
Kate Therapeutics is a biotechnology company specializing in the development of adeno-associated virus (AAV)-based gene therapies aimed at treating genetically defined muscle and heart diseases. The company employs innovative technology platforms that enhance tissue-specific delivery and gene regulation, effectively addressing the limitations of existing gene therapies. By utilizing novel capsids, Kate Therapeutics achieves superior muscle transduction and liver de-targeting compared to naturally occurring serotypes, facilitating more effective tissue transduction at significantly lower viral doses. This advancement helps to overcome major challenges in muscle gene delivery, ultimately improving treatment outcomes for patients with these specific conditions.

Akamis Bio

Debt Financing in 2023
Akamis Bio is a clinical-stage oncology company dedicated to advancing cancer treatment through its innovative Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform. The company develops a portfolio of therapeutics specifically targeting solid tumors, aiming to enhance patients' immune responses to recognize and eradicate cancer cells. By harnessing a proprietary intravenously administered viral platform, Akamis Bio focuses on delivering effective gene therapies that address the needs of cancer patients, striving to improve their quality of life and treatment outcomes.

Dantari

Series A in 2022
Dantari is a biotechnology company focused on developing innovative treatments for serious diseases, including cancer and disorders of the central nervous system. The company has created a pharmaceutical platform that facilitates the research and development of both small and large molecule therapeutics capable of crossing the blood-brain barrier. This advancement allows for the rapid progression of therapies aimed at delivering meaningful medical improvements to patients' lives. Additionally, Dantari's novel antibody-drug conjugate platform features a higher drug-to-antibody ratio compared to traditional approaches, along with the ability to release therapeutic payloads in a tunable manner. This technology enhances the efficacy and therapeutic potential of its medicines, ultimately aiming to improve patient health outcomes.

Acelyrin

Series C in 2022
Acelyrin is a late-stage clinical biopharmaceutical company dedicated to advancing new treatment options for patients. The company specializes in identifying, acquiring, and accelerating the development and commercialization of promising drug candidates. By leveraging its expertise, Acelyrin aims to rapidly bring transformative medicines to market, ultimately improving patient outcomes and quality of life.

ArsenalBio

Series B in 2022
ArsenalBio is a programmable cell therapy company established in 2019, focused on developing and commercializing innovative immune cell therapies, particularly for cancer treatment. The company utilizes advanced technologies, including CRISPR-based genome engineering, synthetic biology, and machine learning, to create multifunctional T-cell therapies. ArsenalBio's approach involves the precise insertion of large synthetic DNA sequences, enabling the generation of next-generation autologous T-cell therapies. By integrating these cutting-edge methods, ArsenalBio aims to enhance the effectiveness and safety of immune cell therapies, reduce costs for healthcare providers, and improve market access, ultimately broadening patient outcomes and making these therapies more widely available.

Sinogen Biopharma

Series A in 2022
Sinogen Biopharma is founded with a vision to bridge China's biotech innovation to the US pharma market. The company licenses and develops innovative drugs from China.

Neuron23

Series C in 2022
Neuron23, Inc. is a biotechnology company focused on developing and manufacturing innovative medicines for genetic disorders, particularly targeting neurological and immunological diseases. Founded in 2018 and headquartered in South San Francisco, California, with an additional office in Munich, Germany, the company utilizes advanced artificial intelligence technology and cutting-edge genetic research to enhance drug discovery. Neuron23 aims to create effective treatments for conditions such as Parkinson's disease and Alzheimer's disease, leveraging its AI-enabled platforms to identify and develop therapeutics that address the needs of patients suffering from these debilitating disorders.

Star Therapeutics

Venture Round in 2022
Star Therapeutics is a biotechnology company focused on developing innovative therapies for a wide range of rare diseases. The company aims to identify rare diseases that share common biological mechanisms, allowing it to create novel therapeutics capable of treating multiple conditions with a single treatment. This approach not only enhances the potential for effective solutions but also provides pharmaceutical companies with opportunities to address several rare diseases simultaneously. By targeting a diverse array of conditions, Star Therapeutics strives to significantly improve the lives of millions of patients affected by these challenging health issues.

Electra Therapeutics

Series B in 2022
Electra Therapeutics is a clinical stage biotechnology company focused on developing therapies aimed at treating immunological diseases and cancer. The company specializes in targeting signal regulatory proteins (SIRP) to deplete pathological immune cells. Its lead product candidate, ELA026, is a monoclonal antibody currently in clinical development for secondary hemophagocytic lymphohistiocytosis (sHLH), a severe hyperinflammatory condition with no existing approved treatments. In addition to ELA026, Electra has two preclinical programs under development, highlighting its commitment to addressing unmet medical needs in the field of immunology and oncology.

Kyverna Therapeutics

Series B in 2022
Kyverna Therapeutics, Inc. is a cell therapy company focused on developing innovative treatments and potential cures for serious autoimmune diseases. Founded in 2018 and based in Berkeley, California, the company utilizes advanced T cell engineering and synthetic biology technologies to target and eliminate autoreactive immune cells that contribute to inflammatory conditions. By addressing the underlying causes of these diseases, Kyverna Therapeutics aims to offer effective solutions for patients suffering from autoimmune disorders.

Acelyrin

Series B in 2021
Acelyrin is a late-stage clinical biopharmaceutical company dedicated to advancing new treatment options for patients. The company specializes in identifying, acquiring, and accelerating the development and commercialization of promising drug candidates. By leveraging its expertise, Acelyrin aims to rapidly bring transformative medicines to market, ultimately improving patient outcomes and quality of life.

Recludix Pharma

Series A in 2021
Recludix Pharma is a biotechnology company focused on drug discovery, specifically developing potent and selective inhibitors for challenging protein targets associated with cancer and autoimmune diseases. The company utilizes a unique platform that integrates custom-generated DNA-encoded libraries, massively parallel determination of structure-activity relationships, and proprietary screening tools. This innovative approach aims to enhance the identification and development of small molecule medicines, allowing medical professionals to create precision therapies tailored to specific protein targets. By addressing complex biological challenges, Recludix Pharma strives to advance treatment options in the healthcare sector.

Expansion Therapeutics

Series B in 2021
Expansion Therapeutics is a drug discovery and development company focused on creating small molecule medicines for RNA-mediated diseases. The company specializes in developing novel RNA-targeted drug candidates that aim to address a wide range of severe medical conditions. By leveraging its innovative technology, Expansion Therapeutics seeks to provide transformative oral treatment options, enhancing the therapeutic landscape for patients suffering from these complex diseases.

3T Biosciences

Series A in 2021
3T Biosciences, Inc. is an immunotherapy company founded in 2017 and headquartered in Menlo Park, California. The company focuses on developing innovative drugs and medical research facilities aimed at offering cures for cancer-related diseases. By leveraging synthetic biology and machine learning, 3T Biosciences seeks to discover novel targets for treating cancer and other T-cell-mediated diseases, thereby enhancing treatment options available to healthcare providers and improving patient outcomes.

Capsida

Series A in 2021
Capsida is a biotechnology company focused on developing targeted gene therapies for monogenic and sporadic disorders affecting both the central nervous system and other areas of the body. The company utilizes a proprietary adeno-associated virus (AAV) engineering platform, which creates capsids specifically designed to target particular tissues and cells within affected organs. This advanced approach not only aims to enhance the efficacy of the therapies by ensuring they reach the intended sites of action, but also minimizes the impact on non-target tissues, thereby improving patient health outcomes in the treatment of life-threatening genetic disorders.

Dantari

Funding Round in 2021
Dantari is a biotechnology company focused on developing innovative treatments for serious diseases, including cancer and disorders of the central nervous system. The company has created a pharmaceutical platform that facilitates the research and development of both small and large molecule therapeutics capable of crossing the blood-brain barrier. This advancement allows for the rapid progression of therapies aimed at delivering meaningful medical improvements to patients' lives. Additionally, Dantari's novel antibody-drug conjugate platform features a higher drug-to-antibody ratio compared to traditional approaches, along with the ability to release therapeutic payloads in a tunable manner. This technology enhances the efficacy and therapeutic potential of its medicines, ultimately aiming to improve patient health outcomes.

Neuron23

Series A in 2020
Neuron23, Inc. is a biotechnology company focused on developing and manufacturing innovative medicines for genetic disorders, particularly targeting neurological and immunological diseases. Founded in 2018 and headquartered in South San Francisco, California, with an additional office in Munich, Germany, the company utilizes advanced artificial intelligence technology and cutting-edge genetic research to enhance drug discovery. Neuron23 aims to create effective treatments for conditions such as Parkinson's disease and Alzheimer's disease, leveraging its AI-enabled platforms to identify and develop therapeutics that address the needs of patients suffering from these debilitating disorders.

Neuron23

Series B in 2020
Neuron23, Inc. is a biotechnology company focused on developing and manufacturing innovative medicines for genetic disorders, particularly targeting neurological and immunological diseases. Founded in 2018 and headquartered in South San Francisco, California, with an additional office in Munich, Germany, the company utilizes advanced artificial intelligence technology and cutting-edge genetic research to enhance drug discovery. Neuron23 aims to create effective treatments for conditions such as Parkinson's disease and Alzheimer's disease, leveraging its AI-enabled platforms to identify and develop therapeutics that address the needs of patients suffering from these debilitating disorders.

Acelyrin

Series A in 2020
Acelyrin is a late-stage clinical biopharmaceutical company dedicated to advancing new treatment options for patients. The company specializes in identifying, acquiring, and accelerating the development and commercialization of promising drug candidates. By leveraging its expertise, Acelyrin aims to rapidly bring transformative medicines to market, ultimately improving patient outcomes and quality of life.

Kyverna Therapeutics

Series A in 2020
Kyverna Therapeutics, Inc. is a cell therapy company focused on developing innovative treatments and potential cures for serious autoimmune diseases. Founded in 2018 and based in Berkeley, California, the company utilizes advanced T cell engineering and synthetic biology technologies to target and eliminate autoreactive immune cells that contribute to inflammatory conditions. By addressing the underlying causes of these diseases, Kyverna Therapeutics aims to offer effective solutions for patients suffering from autoimmune disorders.

Tmunity

Series B in 2019
Tmunity Therapeutics, Inc. is a biotherapeutics company based in Philadelphia, Pennsylvania, that specializes in the development of innovative immunotherapies for cancer, infectious diseases, and autoimmune disorders. Founded in 2015, Tmunity focuses on harnessing the potential of T cells through novel technologies, including T Cell Receptor (TCR) engineered T cells and regulatory T cells (Treg). The company has developed advanced platforms that allow for precise control over T cell activation and direction in vivo, as well as proprietary methods for activating, expanding, and genetically engineering T cells sourced from peripheral blood, cord blood, and tumors. Tmunity aims to advance personalized next-generation immunotherapies and has a team of experts with extensive experience in T-cell biology and clinical development, enhancing its capability to conduct safe and effective clinical trials. Its robust manufacturing platform supports multi-center clinical studies across various therapeutic areas, positioning Tmunity at the forefront of immunotherapy innovation.

ArsenalBio

Series A in 2019
ArsenalBio is a programmable cell therapy company established in 2019, focused on developing and commercializing innovative immune cell therapies, particularly for cancer treatment. The company utilizes advanced technologies, including CRISPR-based genome engineering, synthetic biology, and machine learning, to create multifunctional T-cell therapies. ArsenalBio's approach involves the precise insertion of large synthetic DNA sequences, enabling the generation of next-generation autologous T-cell therapies. By integrating these cutting-edge methods, ArsenalBio aims to enhance the effectiveness and safety of immune cell therapies, reduce costs for healthcare providers, and improve market access, ultimately broadening patient outcomes and making these therapies more widely available.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.